Barbieri C, Baruto C, Sala M, Bigatti G, Parodi M, Bellini P, Bevilacqua M
Eur J Clin Pharmacol. 1985;29(1):123-5. doi: 10.1007/BF00547381.
The possible relationship between cortisol inhibition induced by deflazacort, a new glucocorticoid, and impairment of prolactin (PRL) and thyrotropin (TSH) secretion in healthy volunteers has been investigated. In 8 healthy subjects deflazacort pretreatment partly inhibited cortisol secretion but did not affect basal or TRH-stimulated secretion of PRL and TSH in comparison to placebo. After dexamethasone, there was the anticipated complete suppression of cortisol secretion, no change in PRL secretion, either in basal conditions or after TRH, and significant inhibition of the TSH response to TRH. No significant change in GH, aldosterone or renin secretion was observed after deflazacort or dexamethasone.
已对新型糖皮质激素地夫可特诱导的皮质醇抑制与健康志愿者催乳素（PRL）和促甲状腺激素（TSH）分泌受损之间的可能关系进行了研究。在8名健康受试者中，与安慰剂相比，地夫可特预处理部分抑制了皮质醇分泌，但不影响PRL和TSH的基础分泌或促甲状腺激素释放激素（TRH）刺激的分泌。地塞米松治疗后，如预期的那样，皮质醇分泌被完全抑制，PRL分泌在基础状态或TRH刺激后均无变化，并且TSH对TRH的反应受到显著抑制。地夫可特或地塞米松治疗后，生长激素（GH）、醛固酮或肾素分泌未观察到显著变化。
